Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Therapeutic Potential
100%
Chronic Myeloid Leukemia
100%
BCR-ABL1
100%
T315I
100%
ATP-binding Pocket
50%
Amino Acids
25%
Signaling Pathway
25%
Threonine
25%
Leucine
25%
Kinase Activity
25%
Dasatinib
25%
Steric Hindrance
25%
Kinase Domain
25%
Resistance Development
25%
Imatinib
25%
Physical Disability
25%
Nilotinib
25%
Second-generation Tyrosine Kinase Inhibitors
25%
Imatinib Therapy
25%
Structural Biology
25%
ABL1 Kinase
25%
Gatekeeper Residue
25%
ATP-competitive Inhibitors
25%
Resistance Mechanism
25%
Biochemistry, Genetics and Molecular Biology
Adenosine Triphosphate
100%
Kinase
100%
Phosphotransferase
100%
Imatinib
66%
Enzyme
33%
Amino Acids
33%
Signal Transduction
33%
Competitive Inhibition
33%
Tyrosine Kinase Inhibitor
33%
Stereospecificity
33%
Dasatinib
33%
Threonine
33%
Nilotinib
33%
Isoleucine
33%
Medicine and Dentistry
Phosphotransferase
100%
Adenosine Triphosphate
100%
Chronic Myelogenous Leukemia
100%
Imatinib
66%
Signal Transduction
33%
Threonine
33%
Amino Acid
33%
Enzymes
33%
Competitive Inhibition
33%
Dasatinib
33%
Tyrosine-Kinase Inhibitor
33%
Isoleucine
33%
Nilotinib
33%
Diseases
33%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphotransferase
100%
Adenosine Triphosphate
100%
Chronic Myeloid Leukemia
100%
Imatinib
66%
Threonine
33%
Amino Acid
33%
Enzymes
33%
Competitive Inhibitor
33%
Isoleucine
33%
Protein Tyrosine Kinase Inhibitor
33%
Dasatinib
33%
Nilotinib
33%
Diseases
33%